Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics

Scholarly Works

• Mohamed, H. R. H.; Hakeem, G. M.; Latif, Y. A.; Elnawasani, S. H.; Nagy, M.; Mohamed, B. A.; Essam, R.; Safwat, G. Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells. Scientific reports 2025, 15, 20144. doi:10.1038/s41598-025-05088-9
• Akbari, B.; Hasan, M. M.; Islam, S. M. Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances. Journal of drug targeting 2025, 1–20. doi:10.1080/1061186x.2025.2520306
• Pacholczak-Madej, R.; Meluch, M.; Püsküllüoğlu, M. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochimica et biophysica acta. Reviews on cancer 2025, 1880, 189369. doi:10.1016/j.bbcan.2025.189369
• Tasleem, M. W.; Rajpoot, S. R.; Zhang, H. Advances in cancer therapeutics with aptamer-functionalized ZIF-8 formulations for site-specific drug delivery. International journal of pharmaceutics 2025, 681, 125816. doi:10.1016/j.ijpharm.2025.125816
• Todaria, M.; Awasthi, R. PLGA nanoparticles as promising drug delivery carrier: the future of skin cancer treatment. Journal of Umm Al-Qura University for Applied Sciences 2025. doi:10.1007/s43994-025-00245-2
• Barattini, C.; Volpe, A.; Gori, D.; Lopez, D.; Ventola, A.; Papa, S.; Montanari, M.; Canonico, B. Early Development of an Innovative Nanoparticle-Based Multimodal Tool for Targeted Drug Delivery: A Step-by-Step Approach. Cells 2025, 14, 670. doi:10.3390/cells14090670
• Guzmán-Sastoque, P.; Rodríguez, C. F.; Monsalve, M. C.; Castellanos, S.; Manrique-Moreno, A.; Reyes, L. H.; Cruz, J. C. Nanotheranostics Revolutionizing Gene Therapy: Emerging Applications in Gene Delivery Enhancement. Journal of Nanotheranostics 2025, 6, 10. doi:10.3390/jnt6020010
• Curry, S. D.; Bower, B. M.; Saemundsson, S. A.; Goodwin, A. P.; Cha, J. N. Binding affinity and transport studies of engineered photocrosslinkable affibody-enzyme-nanoparticle constructs. Nanoscale advances 2025, 7, 2239–2247. doi:10.1039/d4na00823e
• Zhang, D.; Zhang, H.; Yang, Y.; Jin, Y.; Chen, Y.; Wu, C. Advancing tissue analysis: Integrating mass tags with mass spectrometry imaging and immunohistochemistry. Journal of proteomics 2025, 316, 105436. doi:10.1016/j.jprot.2025.105436
• Chen, Q.; Jin, J.; Li, P.; Wang, X.; Wang, Q. Navigating Glioma Complexity: The Role of Abnormal Signaling Pathways in Shaping Future Therapies. Biomedicines 2025, 13, 759. doi:10.3390/biomedicines13030759
• Soni, S.; Megha, K.; Shah, V. B.; Shah, A. C.; Bhatt, S.; Merja, M.; Khadela, A. Unlocking the therapeutic potential of antibody-drug conjugates in targeting molecular biomarkers in non-small cell lung cancer. Journal of the Egyptian National Cancer Institute 2025, 37, 6. doi:10.1186/s43046-025-00264-4
• Asad, S.; Ahl, D.; Suárez-López, Y. D. C.; Erdélyi, M.; Phillipson, M.; Teleki, A. Click Chemistry-Based Bioconjugation of Iron Oxide Nanoparticles. Small (Weinheim an der Bergstrasse, Germany) 2025, 21, e2407883. doi:10.1002/smll.202407883
• Park, W.; Choi, J.; Hwang, J.; Kim, S.; Kim, Y.; Shim, M. K.; Park, W.; Yu, S.; Jung, S.; Yang, Y.; Kweon, D.-H. Apolipoprotein Fusion Enables Spontaneous Functionalization of mRNA Lipid Nanoparticles with Antibody for Targeted Cancer Therapy. ACS nano 2025, 19, 6412–6425. doi:10.1021/acsnano.4c16562
• Thanasi, I. A.; Bouloc, N.; McMahon, C.; Wang, N.; Szijj, P. A.; Butcher, T.; Rochet, L. N. C.; Love, E. A.; Merritt, A.; Baker, J. R.; Chudasama, V. Formation of mono- and dual-labelled antibody fragment conjugates via reversible site-selective disulfide modification and proximity induced lysine reactivity. Chemical science 2025, 16, 2763–2776. doi:10.1039/d4sc06500j
• Bikorimana, J. P.; Farah, R.; Abusarah, J.; Mandl, G. A.; Erregragui, M. A.; Gonçalves, M. P.; Talbot, S.; Matar, P.; Lahrichi, M.; El-Hachem, N.; Rafei, M. Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy. iScience 2025, 28, 111957. doi:10.1016/j.isci.2025.111957
• Kapare, H.; Bhosale, M.; Bhole, R. Navigating the future: Advancements in monoclonal antibody nanoparticle therapy for cancer. Journal of Drug Delivery Science and Technology 2025, 104, 106495. doi:10.1016/j.jddst.2024.106495
• Abdelhamid, M. S.; Wadan, A.-H. S.; Saad, H. A.; El-Dakroury, W. A.; Hageen, A. W.; Mohammed, D. H.; Mourad, S.; Mohammed, O. A.; Abdel-Reheim, M. A.; Doghish, A. S. Nanoparticle innovations in targeted cancer therapy: advancements in antibody-drug conjugates. Naunyn-Schmiedeberg's archives of pharmacology 2025, 398, 6369–6389. doi:10.1007/s00210-024-03764-7
• Li, K.; Gui, S.; Wang, N.; Li, X.; Zhao, C.; Liu, M.; Zhang, Z. Sequential pH/GSH-responsive stealth nanoparticles for co-delivery of anti-PD-1 antibody and paclitaxel to enhance chemoimmunotherapy of lung cancer. European journal of medicinal chemistry 2025, 285, 117273. doi:10.1016/j.ejmech.2025.117273
• Kumar, B. V.; Shukla, A.; Ahmed, N.; Solanki, K.; Srivastava, N.; Saraf, S. A.; Meher, N. Antibody drug conjugates integrated with lipid nanocarrier for cancer theranostics. Lipid-Drug Conjugates; Elsevier, 2025; pp 333–363. doi:10.1016/b978-0-443-33382-8.00012-1
• Vignesh, A.; Menaka, C.; Amal, T. C.; Selvakumar, S.; Vasanth, K. Exploring the dual impact of nanoparticles on human well-being: A comprehensive review of risks and benefits. Next Nanotechnology 2025, 8, 100223. doi:10.1016/j.nxnano.2025.100223

Explore citations to this article at